11.4.1 Corticosteroids Topical corticosteroids should normally only be used with expert supervision | |
GREEN Betamethasone eye/ear/nose drops 0.1% |
GREEN Betnesol-N® eye/ear/nose drops |
GREEN Dexamethasone eye drops 0.1 (Maxidex®) |
GREEN Fluorometholone eye drops 0.1% |
GREEN Maxitrol® eye drops, eye ointment |
GREEN Prednisolone eye/ear drops 0.5% |
GREEN Predsol-N® eye/ear drops |
AMBER Prednisolone eye drops 1% (forte)(specialist use only) |
|
For the treatment of post operative inflammation following ocular surgery in patients who are at risk of corticosteroid |
induced raised intra-ocular pressure. |
AMBER Loteprednol drops 0.5% (specialist use only) |
RED Dexamethasone intravitreal implant 700mcg (specialist use only) |
(For further information, see NICE TA229) |
|
NICE Guidance for the treatment of sight problems caused by diabetic macular oedema |
NICE TA824* Dexamethasone intravitreal implant is recommended as an option for treating visual impairment caused by |
diabetic macular oedema in adults only if their condition has not responded well enough to, or if they |
cannot have non-corticosteroid therapy. See full guidance |
*NICE TA824 updates and replaces NICE TA349 (September 2022( |
|
RED Dexamethasone intravitreal implant 700mcg (specialist use only) ICS Commissioned, Blueteq required |
|
|
NICE guidance for treating chronic diabetic macular oedema after an inadequate response to prior therapy |
NICE TA301* Fluocinolone acetonide intravitreal implant is recommended as an option for treating chronic diabetic |
macular oedema that is insufficiently responsive to available therapies only if: |
> the implant is to be used in an eye with an intraocular (pseudophakic) lens and |
> the manufacturer provides fluocinolone acetonide intravitreal implant with the discount agreed in the |
patient access scheme. |
*[Rapid review of NICE TA271] |
RED Fluocinolone acetonide intravitreal implant (Iluvien®) NHS England Commissioned |
|
NICE guidance for treating visual impairment due to diabetic macular oedema in adults |
NICE TA799 Faricimab is recommended as an option for treating visual impairment due to diabetic macular oedema |
in adults, only if: |
> the eye has a central retinal thickness of 400 micrometres or more at the start of treatment |
> the company provides faricimab according to the commercial arrangement |
RED Faricimab (Vabysmo solution for injection vials) ICB Commissioned [formerly CCG]. Blueteq required |
|
NICE guidance for treating non-infectious uveitis in adults |
NICE TA460 Adalimumab is recommended as an option for treating non-infectious uveitis in the posterior segment |
of the eye in adults with inadequate response to corticosteroids, only if there is: |
> active disease (that is, current inflammation in the eye) and |
> inadequate response or intolerance to immunosuppressants and |
> systemic disease or both eyes are affected (or 1 eye is affected if the second eye has poor visual acuity) |
and |
> worsening vision with a high risk of blindness (for example, risk of blindness that is similar to that seen in |
people with macular oedema). |
Dexamethasone intravitreal implant is recommended as an option for treating non-infectious uveitis in the |
posterior segment of the eye in adults, only if there is: |
> active disease (that is, current inflammation in the eye) and |
> worsening vision with a risk of blindness. |
RED Adalimumab solution for injection NHS England Commissioned |
RED Dexamethasone intravitreal implant 700mcg (specialist use only) NHS England Commissioned |
|
NICE guidance for treating non-infectious uveitis |
NICE TA590 Fluocinolone acetonide intravitreal implant is recommended as an option for preventing relapse in |
recurrent non-infectious uveitis affecting posterior segment of the eye. It is recommended only if the |
company provides it according to the commercial arrangement. |
RED Fluocinolone acetonide intravitreal implant (Iluvien®) NHS England Commissioned |
|
Dexamethasone intravitreal implant 700mcg [Ozurdex®] |
Approved as second line treatment when there is no significant effectiveness and response of the diabetic macular |
oedema to previous Anti VEGF |
|
RED Dexamethasone intravitreal implant 700mcg (specialist use only) [Ozurdex®] |
CCG Commissioned Blueteq form required |
11.4.2 Other anti-inflammatory preparations |
Used to treat inflammation and allergic conjunctivitis |
GREEN Sodium cromoglicate eye drops 2% (1st line option) |
GREEN Otrivine-Antistin® eye drops |
|
Seasonal Allergic Conjunctivitis |
GREEN Olopatadine eye drops 1mg/ml [maximum use 4 months] |
restricted |
(Consultant initiation only. 2nd line option, when first line of management fails or not adequate |
GREEN Ketotifen UDV eye drops 0.25mg/ml PF [Ketofall®] |
restricted (option when preservative free product is required) |
|
BACK to main chapter |